Sitemap | Contact Us  

Welcome To Taj Pharmaceuticals Ltd API      

About Worldwide  |     FAQs    |    Careers     | |        Media Center  |  |    Taj Pharmaceuticals  World   | |     TAJ Group 

      © 2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved

api image Irinotecan-Hcl

      India              Latin America/ Caribbean            Africa & Middle East              Asia              Russia              Europe  

Isradipine Manufacturers in India Suppliers Isradipine Exporters Distributors Isradipine api active pharmaceuticals ingredients Isradipine manufacturers Side Effects bulk drugs raw material Isradipine companies Side Effects Importers Isradipine Isradipine Exporters Isradipine exporters FDA Isradipine DMF Symptoms Generic Taj Pharmaceuticals Ltd.

active pharmaceutical ingredients suppliers pharmaceutical Isradipine manufacturing pharmaceutical drugs pharmaceutical intermediates Isradipine pharmaceutical chemicals pharmaceutical raw materials Isradipine active pharmaceutical ingredients Isradipine committee active pharmaceutical ingredients manufacturer Isradipine Active Pharmaceutical Ingredients manufacturer Isradipine exporter drug ingredients pharmaceuticals

Pharmaceuticals API Manufacturer Isradipine, Isradipine manufacturer India, Isradipine product, Isradipine products, Api preparation, Certificate of Analysis API manufacturer product, Isradipine anti ulcer product, Certificate of Origin COA Isradipine COS Isradipine, pharmaceutical generic, pharmaceutical drug, medical, Isradipine pharma healthcare, pharma patents, contract MSDS manufacturing Trader Isradipine pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Isradipine expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Isradipine DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Isradipine ingredients, api, HIV Isradipine, tablets, capsules, syrup & protein Isradipine powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Isradipine gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Isradipine WHO, UKMHRA Approval

   API >>>
   Pharmaceuticals API List
   Product Development
   Product Search
   Agro Chemicals
   Custom Pharma Services
   Contact Us

Irinotecan-Hcl img.





HOME >> API >> API List 2 >> Isradipine >> Interaction

Isradipine  CAS Registry Number 75695-93-1


Isradipine CAS Registry Number 75695-93-1

 Drug interactions (not inclusive)

* Grapefruit juice with certain dihydropyridines
* All medications that can lower blood pressure
* Fentanyl has been reported to cause severe hypotension when given with certain calcium channel blockers
* This reaction may occur with all calcium channel blockers, but no data available
* H2-receptor antagonists may increase the bioavailability of many of the dihydropyridine calcium channel blockers

(isradipine) has been safely coadministered with nitroglycerin.

Hydrochlorothiazide: A study in normal healthy volunteers has shown that concomitant administration of DynaCirc® (isradipine) and hydrochlorothiazide does not result in altered pharmacoktnetics of either drug. In a study in hypertensive patients, addition of isradipine to existing hydrochlorothiazide therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect.

Propranolol: In a single dose study in normal volunteers, coadministration of propranolol had a small effect on the rate but no effect on the extent of isradipine bioavailability. Significant increases In AUC (27%) and Cmax (58%) and decreases in tmax (23%) of propranolol were noted in this study. However, concomitant administration of 5 mg b.i.d. isradipine and 40 mg b.i.d. propranolol to healthy volunteers under steady-state conditions had no relevant effect on either drug's bioavailability, AUC and Cmax, differences were <20% between isradipine given singly and in combination with propranolol, and between propranolol given singly and in combination with isradipine.
Rifampicin: In a study in healthy volunteers, a six-day course of rifampicin at 600 mg/day followed by a single 5 mg dose of isradipine resulted in a reduction in isradipine levels to below detectable limits. If rifampicin therapy is required, isradipine concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of isradipine. Warfarin: In a study in healthy volunteers, no clinically relevant pharmacokinetic or pharmacodynamic interaction between isradipine and racemic warfarin was seen when two single oral doses of warfarin (0.7 mg/kg body weight) were administered during 11 days of multipledose treatment with 5 mg b.i.d. isradipine. Neither racemic warfarin nor isradipine binding to plasma proteins in vitro was altered by the addition of the other drug.

Information Associated with Product:
Product Enquiry Product Quotation Sample Request Place Your Order  
Product Enquiry Product Quotation Sample Request Place Your Order  

Taj Pharmaceuticals API Logo


Api Manufacturer,Export,Supplies,Manufacturing


Gemcitabine Hcl


Granisetron Hcl

Ibandronate Sodium

Imatinib Mesylate


Irinotecan Hcl





Losartan Potassium

Loteprednol Etabonate

Magnesium Valproate


Memantine Hcl


Metamizol Magnesium


Metformin Hcl

Metoprolol Tartrate




Mometasone Furoate

Naltrexone Hcl


Copyright © Taj Pharmaceuticals Ltd. | Privacy Policy | Terms & Conditions | Sitemap

Investor Relations    Feedback     Contact Worldwide    Sitemap


taj group logo
© 2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Ltd products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.